Core Insights - Xiaofang Pharmaceutical experienced a 3.13% decline in stock price on November 17, with a trading volume of 80.09 million yuan [1] - The company reported a financing net purchase of 2.84 million yuan on the same day, with a total financing balance of 92.34 million yuan, representing 5.55% of its market capitalization [1] - For the period from January to September 2025, Xiaofang Pharmaceutical achieved a revenue of 397 million yuan, reflecting a year-on-year growth of 8.17% [2] Financing and Trading Activity - On November 17, Xiaofang Pharmaceutical had a financing buy amount of 7.44 million yuan and a financing repayment of 4.60 million yuan, resulting in a net financing purchase of 2.84 million yuan [1] - The total financing balance of 92.34 million yuan is above the 50th percentile level over the past year, indicating a relatively high level of financing activity [1] - The company had no short selling activity on November 17, with a short selling balance of 0.00 yuan, which is at the 90th percentile level over the past year [1] Company Performance - Xiaofang Pharmaceutical's main business revenue composition includes digestive products (51.05%), skin products (39.79%), and ear, nose, and throat products (9.08%) [1] - As of November 10, the number of shareholders increased by 2.88% to 13,700, while the average circulating shares per person decreased by 2.80% to 3,956 shares [2] - Cumulatively, the company has distributed 353 million yuan in dividends since its A-share listing [3] Shareholder Structure - As of September 30, 2025, the top ten circulating shareholders include a new entrant, GF Multi-Dimensional Emerging Stock (003745), holding 753,100 shares [3] - Notably, CITIC Securities' mixed funds have exited the top ten circulating shareholders list [3]
小方制药11月17日获融资买入744.22万元，融资余额9234.18万元